Status:

COMPLETED

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Lead Sponsor:

Abbott

Conditions:

Human Immunodeficiency Virus Infections

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study was to compare the safety and tolerability of the to-be-marketed lopinavir/ritonavir (LPV/r) tablet formulation with the marketed soft gel capsule (SGC) formulation and to co...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Subjects were human immunodeficiency virus type 1 (HIV-1) positive, antiretroviral naïve adults at least 18 years of age with \< 7 days of prior antiretroviral therapy.
  • Subjects had plasma HIV-1 ribonucleic acid (RNA) levels \>= 1,000 copies/mL at screening and were not acutely ill.
  • Female subjects were nonpregnant and nonlactating.
  • Exclusion Criteria
  • Subjects were excluded if screening laboratory analyses showed any of the following abnormal laboratory results:
  • Presence of hepatitis B surface antigen (HBsAg)
  • Hemoglobin \<= 8.0 g/dL
  • Absolute neutrophil count \<= 750 cells/microliter
  • Platelet count \<= 50,000 per mL
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>= 3.0 x Upper Limit of Normal (ULN)
  • Calculated creatinine clearance \< 50 mL/min

Exclusion

    Key Trial Info

    Start Date :

    November 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 1 2008

    Estimated Enrollment :

    664 Patients enrolled

    Trial Details

    Trial ID

    NCT00262522

    Start Date

    November 1 2005

    End Date

    July 1 2008

    Last Update

    February 6 2012

    Active Locations (129)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 33 (129 locations)

    1

    Site Reference ID/Investigator# 823

    Phoenix, Arizona, United States, 85006

    2

    Site Reference ID/Investigator# 846

    Phoenix, Arizona, United States, 85012

    3

    Site Reference ID/Investigator# 851

    Beverly Hills, California, United States, 90211

    4

    Site Reference ID/Investigator# 872

    Fountain Valley, California, United States, 92708